JPRN-UMIN000010095已完成2 期
A Phase II, Open-label Single-Arm Study to Evaluate the efficacy and Safety of Vandetanib in Patients with RET Fusion-positive Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer - LURET
ational Cancer Center Hospital East0 个研究点目标入组 17 人开始时间: 2013年2月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 17
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.The last dose of prior chemotherapy or other anti-cancer therapy is discontinued less than 4 weeks before the start of study therapy 2.The last radiation therapy within 4 weeks before the start of study therapy 3.Major surgery within 4 weeks before the start of study therapy, or incompletely healed surgical incision 4.Any unresolved toxicity > CTCAE grade 2 from previous anti-cancer therapy 5.Significant cardiac event, superior vena cava syndrome, New York Heart Association classification of heart disease ≥2, within 12 weeks before registration 6.History of arrhythmia, which is symptomatic or requires treatment (CTCAE grade 3) 7.Congenital long QTc syndrome 8.QTc prolongation with other medications that required discontinuation of that medication 9.Potassium concentration <4.0 mEq/L, calcium or magnesium concentrations outside of normal limits at each site despite supplementation 10.Currently pregnant or breast feeding 11.Any concomitant medications that have been associated with Torsades de Pointes or strong inducers of CYP3A4 function within 2 weeks of start of study treatment. 12.Unstable brain metastases or spinal cord compression that requires treatment 13.Hypertension not controlled by medical therapy 14.Previous or current malignancies of other histologies within the last 5 years 15.Evidence of severe or uncontrolled systemic disease 16. Any evidence of clinically active interstitial lung disease 17.Previous exposure to vandetanib
研究者
相似试验
已完成
2 期
A Phase II, Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Trastuzumab (Herceptin) in Patients with Her2 Overexpression/Amplification/Mutation-Positive, Pretreated, Non-Small Cell Lung Cancer (HER2-CLHERC-B/HOT1303-B)Her2 overexpression/amplification/mutation-positive, pretreated, non-small cell lung cancersJPRN-UMIN000012551Hokkaido Lung Cancer Clinical Study Group10
进行中（未招募）
1 期
A Phase 2 Study to Evaluate the Effectivness and Safety of ADCT-301 in Patients with Relapsed or Refractory Hodgkin LymphomaEUCTR2018-002556-32-FRADC Therapeutics SA100
进行中（未招募）
1 期
A Phase 2 Study to Evaluate the Effectivness and Safety of ADCT-301 in Patients with Relapsed or Refractory Hodgkin LymphomaRelapsed or Refractory Hodgkin LymphomaMedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10020267Term: Hodgkin's disease refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10020234Term: Hodgkin's disease mixed cellularity refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10020233Term: Hodgkin's disease mixed cellularity recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002556-32-DEADC Therapeutics SA100
进行中（未招募）
1 期
A Phase 2 Study to Evaluate the Effectiveness and Safety of ADCT-301 in Patients with Relapsed or Refractory Hodgkin LymphomaEUCTR2018-002556-32-ESADC Therapeutics SA100
进行中（未招募）
1 期
A Phase 2 Study to Evaluate the Effectivness and Safety of ADCT-301 in Patients with Relapsed or Refractory Hodgkin LymphomaEUCTR2018-002556-32-PLADC Therapeutics SA100